A5074330954- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Chronic Lymphocytic Leukemia Research
- Cancer Risks and Factors
- Cancer, Hypoxia, and Metabolism
- Carcinogens and Genotoxicity Assessment
- Angiogenesis and VEGF in Cancer
- Cancer Genomics and Diagnostics
- Cancer-related gene regulation
- Lymphatic System and Diseases
- Pharmaceutical studies and practices
Ministry of Health of the Russian Federation
2024
University of Colorado Denver
2023
Astellas Pharma (United States)
2023
University of Kansas Medical Center
2023
The University of Texas MD Anderson Cancer Center
2023
Children's Hospital Colorado
2023
Leukemia and Lymphoma Society
2023
National Medical Research Center for Hematology
2018-2023
University Clinic of Traumatology
2023
Medical University of South Carolina
2023
Introduction. The identification of mutations in the FLT3 gene is essential for diagnosis, prognosis, and selection treatment strategies acute myeloid leukemia (AML). Aim: to compare main methods used diagnosis patients with AML. Materials methods. Identification was carried out using polymerase chain reaction (PCR) fragment analysis (PCR-FA), double-label PCR-FA, tandem duplication method (TD-PCR), next-generation sequencing (NGS), allele-specific PCR (AS-PCR) who were diagnosed or observed...
Introduction. The current overall effectiveness of acute myeloid leukemia (AML) treatment is largely ensured by the integration transplantation technologies, but not all patients who are indicated to undergo allogeneic hematopoietic stem cells (allo-HSCT) can reach this stage. Aim: analyze time and volume implementation allo-HSCT in with AML first complete remission (1CR). Materials methods. Between January 2020 December 2023, 477 from 43 different regions Russian Federation were referred...
Introduction . Acute myeloid leukaemia (AML) is associated with multiple driver mutations, which prognostic value remains understudied. Aim Assessment of the frequency mutations in various genes and their impact on acute outcome adults. Materials methods The study included 90 adult patients newly diagnosed AML; 76 were aged under 60, 14 60 more years old. Patients had chemotherapy (CT) “7+3” as induction, elder cohort variant low-dose CT hypomethylating agents. molecular genetic status was...
Background. Vascular endothelial growth factor A (VEGFA) is one of the most important factors for regulation hematopoietic stem cells differentiation. It involved in leukemogenesis and central nervous system (CNS) damage acute leukemia. According to literature, VEGFA production by blast increased, but values serum concentration associations with CNS involvement are contradictory. Aim. evaluate VEGFA, VEGFR1, VEGFR2 cerebrospinal fluid patient different types leukemia disease onset during...
Introduction. Achieving complete remission and prolonging event-free survival is the primary task of chemotherapeutic treatment for patients with acute myeloid leukemia (AML). Supportive therapy a possible way to maintain remission. Aim: compare two variants supportive (5+5 6-MP + Mtx) in AML first after completion induction consolidation programs. Materials methods. The single-center randomized study included 34 treated from 2017 2021. median age was 36 (18–56) years, ratio men women 18:16....
Background . One approach to improving overall and relapsefree survival for patients with acute leukemia is allogeneic hematopoietic stem cell transplantation (allo-HSCT). The probability of relapse after allo-HSCT in may be influenced by many factors, including the presence minimal residual disease (MR) before allo-HSCT. Aim. To evaluate relationship between MR first complete remission myeloid (AML) lymphoblastic (ALL). Materials methods study included 241 patients: 143 AML 98 ALL (30...
Background: In patients with relapsed or refractory acute myeloid leukemia (R/R AML) encouraging results have been reported after allogeneic hematopoietic stem cell transplantation (HSCT) following a conditioning regimen sequential melphalan, fludarabine and total body irradiation (FMTBI) (Steckel et al., Br. J. Haematol. 2018; 180:840–853). However, non-relapse mortality (NRM) was up to 45% in elderly (>59 years) higher age associated inferior survival. Aims: We hypothesized that active...
Aim. To analyze the results of treatment in patients with acute myeloid leukemia (AML) within protocols AML-17 and modified (mOML-17) as part two consecutive pilot studies order to develop best strategy for AML aged below 60 years. Materials methods. The study included 89 who were years received mOML-17 protocols. Cytogenetic molecular genetic performed all patients. presence mutations FLT3, NPM1, CEBPa genes was assessed by fragment analysis. 35 underwent a mutTP53, mutRUNX1 using next...
Topic: 4. Acute myeloid leukemia - Clinical Background: AML is heterogeneous disease with much fewer treatment options. 7 + 3 and different high dose ARA-C combinations are still the mainstream approaches for patients that fit intensive therapy. New AZA+ven has emerged elderly or unfit pts, but there few publications about its efficacy as first line in youngs pts de novo AML, especially myelodysplasia related changes (MRC-AML). The question whether allo-HSCT necessary CR1 if MRD-negativity...
Background: Acute myeloid leukemia (AML) is the most common type of acute in adult pts, including pregnant. AML accounts for two-thirds all cases diagnosed during pregnancy. Formulated more than 25 years ago, postulate about neсessity “saving two lives” formed basis a systematic approach to treatment pregnant pts with AML, and allowed develop appropriate clinical protocols. Aims: To assess prognostic impact allo-HSCT conducted CR1 AML. Methods: In total 45 were included multicenter research....
Introduction . Acute leukemias are very rarely diagnosed during pregnancy, which makes large prospective or comparative studies of treatment pregnancy difficult. In 2009, the Russian Lymphoblastic Leukemia Study Group decided to include women with acute lymphoblastic leukemia (ALL) various stages into ALL-2009 clinical study determine predictive role at diagnosis, and estimate efficacy tolerance protocol in pregnant women. Materials methods During period 2009– 2017, 15 Ph-negative ALL aged...
Background:NPM1 gene mutations are found in 30% of acute myeloid leukemia (AML) cases. It is a reliable marker for the evaluation therapy outcome and minimal residual disease (MRD) monitoring. The most often 4bp insertions exon 12, affecting 2 functionally important tryptophan residues (W288 W290) C-terminal region nucleophosmin causing frameshift. As result, leucine-rich motif (L-xxx-V-xx-V-x-L) formed, which signal sequence protein export from nucleus to cytoplasm. Commonly NPM1 detected...